Article Text

other Versions

PDF
Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity
  1. María Ana Martínez Castellanos1,
  2. Shulamit Schwartz2,
  3. Gerardo García-Aguirre1,
  4. Hugo Quiroz-Mercado2
  1. 1Department of Ophthalmology, Asociación para Evitar la Ceguera en México, Hospital “Luis Sanchez Bulnes” I.A.P., Mexico City, Mexico
  2. 2Department of Ophthalmology, Denver Health Medical Center, Affiliated with University of Colorado, Denver, Colorado, USA
  1. Correspondence to Dr Shulamit Schwartz, Department of Ophthalmology, Denver Health Medical Center, Affiliated with University of Colorado, 6740 unit A, E. Cedar Ave., Denver, CO 80224, USA; schwartz330{at}gmail.com

Abstract

Purpose To evaluate ocular outcome in premature infants treated with intravitreal ranibizumab injections for retinopathy of prematurity (ROP) over a period of 3 years.

Methods An interventional case series. Premature infants with high-risk prethreshold or threshold ROP with plus disease received an off label monotherapy with intravitreal injections of ranibizumab. The primary outcome was treatment success defined as regression of neovascularisation (NV) and absence of recurrence. The secondary outcomes were ocular and systemic adverse events and visual acuity.

Results Six eyes were included in the study and treated with intravitreal injections of ranibizumab. All showed complete resolution of NV after a single injection. The anti-angiogenic intravitreal injections allowed for continued normal vessel growth into the peripheral retina, without any signs of disease recurrence or progression during the follow up period. No ocular or systemic adverse effects were observed.

Conclusions Three years of follow up in a small series suggest that intravitreal ranibizumab injections for ROP result in apparently preserved ocular outcome. Further large scale studies are needed to address the long-term safety and efficacy.

  • Retina
  • Child health (paediatrics)

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.